#USA #New York #Gross Law Firm #Rocket Pharmaceuticals #RCKT

Gross Law Firm Alerts Rocket Pharmaceuticals Shareholders

As the legal landscape continues to evolve, the Gross Law Firm has recently reached out to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). The firm emphasizes the urgency for those who purchased shares during the specified class period to act swiftly. The deadline for registering as a lead plaintiff is looming on August 11, 2025. This important notice from the Gross Law Firm is designed to keep investors informed of their rights and the potential for recovery arising from the alleged misconduct of the company.

Rocket Pharmaceuticals has come under scrutiny due to serious allegations pertaining to misleading statements regarding the safety of its clinical trials. According to the complaint, the firm is accused of providing overly optimistic information while suppressing crucial negative data about their drug RP-A501. Notably, investors were not informed of the potential risks tied to Serious Adverse Events (SAEs), which included the unfortunate death of a participant in the clinical trial. This critical oversight not only misled investors but also artificially inflated the stock price until the shocking revelation led to a drastic stock decline.

On May 27, 2025, Rocket Pharmaceuticals announced that the FDA had placed a clinical hold on the Phase 2 study, following the SAE that resulted in fatality. In a shocking twist, Rocket disclosed that a modification to the trial protocol had been made months earlier without alerting stakeholders to this information. This failure to communicate effectively with investors resulted in a steep drop in the company’s stock price, which plummeted to $2.33 per share from $6.27, representing a staggering 37% decrease in mere hours.

Given these developments, the Gross Law Firm encourages all shareholders who bought RCKT shares between February 27, 2025, and May 26, 2025, to consider this class action lawsuit. Being named a lead plaintiff is not a prerequisite for receiving recovery, and all interested investors are urged to contact the law firm for further information and to register. Doing so allows participating shareholders to partake in the ongoing case without incurring any fees.

The Gross Law Firm, recognized nationally for its commitment to investor rights, will ensure that all voices are heard in this case. Their mission revolves around advocating for investors who have faced losses caused by deceitful practices and negligence from corporations. By engaging in this legal process, investors are granted the opportunity to hold Rocket Pharmaceuticals accountable for its actions.

Shareholders can click here to register for the class action and gain access to portfolio monitoring software that will provide ongoing litigation updates. The deadline of August 11, 2025, is not one to overlook, as it marks a pivotal point in the pursuit of justice for affected investors.

Overall, the recent events surrounding Rocket Pharmaceuticals demonstrate the importance of transparency in corporate communications. Investors must remain vigilant and proactive, ensuring that they are informed and ready to act on any potential legal recourse that may arise in the event of corporate misconduct. The Gross Law Firm stands ready to assist and guide shareholders through the complexities of this case, drawing from their dedication to uphold investor rights in the face of corporate irresponsibility.